Contributed equally.

Discussion {#onco13019-sec-0006}
==========

The NEO‐CLASSIC study was designed to investigate the efficacy and safety of perioperative chemotherapy. Thus, with laparoscopic staging, we enrolled patients with T2--4/N+M0 disease. Among the 54 intent‐to‐treat patients, 14.8% of patients were stage II, and the other 85.2% of patients were stage III.

###### Clinical response in the intent‐to‐treat population (*n* = 54)

![](onco13019-tbl-0001){#nlm-graphic-1}

Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

One patient underwent emergency subtotal gastrectomy before assessment.

The ORR was 50%. Although the ORR did not achieve the primary endpoint, the disease control rate was 90.7% (49/54 patients), which created possibilities for radical surgery. The R0 resection rate was one of the secondary study objectives, with 49 patients proceeding to any surgical resection. R0 resection of the primary tumor was achieved in 83.3% of patients (45/54), which was similar to that in previous studies. The survival analysis revealed a 3‐year progression‐free survival (PFS) rate of 43.8%, and a 3‐year overall survival (OS) rate of 47.2%. The median PFS was 20.1 months, with an event rate of 55.6%. However, median OS was 30.77 months. The survival disparity between the CLASSIC study (adjuvant capecitabine and oxaliplatin, with its 78% 5‐year overall survival) and the FLOT4 trial (fluorouracil plus leucovorin, oxaliplatin, and docetaxel) trial and our study (50 months vs. 30.77 months overall survival, respectively) may have resulted from population differences. However, patients in our study had much later disease (T2--4/N+M0) and were typically in stage III.

The proportion of grade 3--4 adverse events (AEs) was 8.5% during perioperative chemotherapy. The most frequent grade 3--4 AEs were neutropenia and leukopenia, and no treatment‐related deaths occurred. All these rates were significantly lower than the FLOT4 trial. Our study also found that XELOX can be delivered with higher dose intensity and better feasibility in the preoperative than in the postoperative setting. No deaths occurred during hospitalization or 30 days after surgery. The median hospitalization time was 9.6 days. Thus, because of its good tolerability profile, XELOX might also be a promising regimen for adjuvant chemotherapy.

Trial Information {#onco13019-sec-0007}
=================

**Disease**Gastric cancer**Stage of Disease/Treatment**Neoadjuvant**Prior Therapy**None**Type of Study -- 1**Phase II**Type of Study -- 2**Single arm**Primary Endpoint**Overall response rate**Secondary Endpoints**Progression‐free survivalOverall survivalPathologic responseSafetyToxicity**Additional Details of Endpoints or Study Design** The primary objective of the study was to determine the ORR of XELOX in the preoperative setting. Sample size was calculated by assuming that a minimum of 47 cases would be required to increase the ORR by 15% (from 40% to 55%). With an estimated 10% dropout rate, 55 patients would have to be recruited. **Investigator\'s Analysis**Inactive because results did not meet primary endpoint

Drug Information {#onco13019-sec-0008}
================

**Drug 1**  **Generic/Working Name**XELOX **Schedule of Administration** The treatment plan was for all patients to receive eight cycles of perioperative XELOX chemotherapy (four cycles preoperatively, four postoperatively). Each 3‐week cycle comprised capecitabine 1,000 mg/m^2^ twice daily on days 1--14, and oxaliplatin 130 mg/m^2^ administered on day 1. Dose reductions or interruptions were allowed to manage potentially serious or life‐threatening AEs. Curative D2 gastrectomy was scheduled within 2--4 weeks after completion of the last cycle of preoperative chemotherapy in patients without progressive disease. Postoperative chemotherapy was started within 8 weeks of surgery. **Drug 2**  **Generic/Working Name**Oxaliplatin **Drug Type**Small molecule **Drug Class**Platinum compound **Dose**130 milligrams (mg) per squared meter (m^2^) **Route**IV **Schedule of Administration**On day 1

Patient Characteristics {#onco13019-sec-0009}
=======================

**Number of Patients, Male**38**Number of Patients, Female**16**Stage** Clinically diagnosed stage T2--4a/N+M0 disease, according to computed tomography and magnetic resonance imaging, and resectable disease according to laparoscopic exploration. Details of patient characteristics are shown in Table [2](#onco13019-tbl-0002){ref-type="table"}. **Age**Median (range): 65 (39∼71)**Number of Prior Systemic Therapies**Median: 0**Performance Status: ECOG**0 --- 51 --- 492 --- 03 --- 0Unknown ---**Cancer Types or Histologic Subtypes**Intestinal, 26Diffuse, 14Mixed, 10Unknown, 4

Primary Assessment Method {#onco13019-sec-0010}
=========================

Number of Patients Screened55Number of Patients Enrolled54Number of Patients Evaluable for Toxicity54Number of Patients Evaluated for Efficacy54Evaluation MethodRECIST 1.1Response Assessment CR*n* = 0 (0%)Response Assessment PR*n* = 27 (50%)Response Assessment SD*n* = 22 (40.7%)Response Assessment PD*n* = 4 (7.4%)(Median) Duration Assessments PFS20.1 months(Median) Duration Assessments OS30.77 monthsOutcome NotesNo deaths occurred during hospitalization or 30 days after surgery. Median hospitalization time was 9.6 days.

Adverse Events {#onco13019-sec-0011}
==============

Grade 3--4 toxicities of chemotherapy are shown in Table [5](#onco13019-tbl-0005){ref-type="table"}. Details related to complications and safety of surgery are shown in Table [6](#onco13019-tbl-0006){ref-type="table"}. 

Serious Adverse Events {#onco13019-sec-1011}
======================
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Assessment, Analysis, and Discussion {#onco13019-sec-0012}
====================================

CompletionStudy completedInvestigator\'s AssessmentInactive because results did not meet primary endpoint

 {#onco13019-sec-1012}

The NEO‐CLASSIC study was designed to investigate the efficacy and safety of perioperative chemotherapy in patients with gastric cancer. Thus, with laparoscopic staging, we enrolled patients with T2--4/N+M0 disease. Among the 54 intent‐to‐treat patients, 14.8% of patients were stage II, and the other 85.2% of patients were stage III. Although the use of diagnostic laparoscopy for staging patients with gastric cancer is not adopted universally, it has substantial value because of its high accuracy and effectiveness, avoidance of unnecessary laparotomy, and its reduced recovery time. Therefore, laparoscopy can improve treatment decision‐making in advanced gastric cancer, and is recommended for patients with resectable gastric cancer \[[1](#onco13019-bib-0001){ref-type="ref"}\].

The objective response rate (ORR) of oxaliplatin and capecitabine (XELOX) as perioperative chemotherapy was evaluated as the primary endpoint of NEO‐CLASSIC, with clinical response evaluated using RECIST (version 1.1). The ORR was 50.0%. The R0 resection rate was one of the secondary study objectives, with 49 patients proceeding to any surgical resection. R0 resection of the primary tumor was achieved in 83.3% of patients (45/54), which was similar to that in previous studies. The R0 resection rate was 84% in the NeoFLOT study \[[2](#onco13019-bib-0002){ref-type="ref"}\], 79% in the MAGIC trial \[[3](#onco13019-bib-0003){ref-type="ref"}\], 84% in the ACCORD trial \[[4](#onco13019-bib-0004){ref-type="ref"}\], and with epirubicin, cisplatin, 5‐fluorouracil or epirubicin, cisplatin, and capecitabine (ECF/ECX) and 57% with fluorouracil plus leucovorin, oxaliplatin, and docetaxel (FLOT) in the FLOT4 trial \[[5](#onco13019-bib-0005){ref-type="ref"}\]. Pathologic response was another important objective of the current trial, and a pathologic complete response (pCR) was reported in 3 of 48 patients (6.3%) from the per‐protocol population who underwent surgery; this was consistent with the 0%--16% rate reported by previous prospective studies \[[6](#onco13019-bib-0006){ref-type="ref"}\], \[[7](#onco13019-bib-0007){ref-type="ref"}\], \[[8](#onco13019-bib-0008){ref-type="ref"}\]. The rate of pathologic response, defined as a complete response or \<10% of the residual cancer remaining, was 20.8% (10/48 patients). According to Japanese Classification of Gastric Cancer criteria \[[9](#onco13019-bib-0009){ref-type="ref"}\], 31.2% of patients (15/45) achieved histologic grade 2--3, which means less than 33.3% of viable tumor cells observed.

We believed that the reasons for the failure to achieve the primary endpoint may be attributed to the following reasons. First, in locally advanced gastric cancer, perigastric lymph nodes were the only target lesions according to RECIST 1.1 criteria, and spiral computed tomography had some limitations in evaluating the primary lesions and lymph nodes. Second, ORR was a widely used preoperative evaluation criterion currently, but it was not an ideal therapeutic indicator of neoadjuvant therapy in gastric cancer.

Although ORR did not achieve the primary endpoint, the disease control rate was 90.7% (49/54 patients), which created possibilities for radical surgery.

An R0 resection rate of 84.3% (59/70 patients) was achieved in the European Organisation for Research and Treatment of Cancer 40954 trial, which used a prolonged (two 48‐day cycles) neoadjuvant cisplatin/5‐fluorouracil‐based regimen \[[10](#onco13019-bib-0010){ref-type="ref"}\]. Several recent studies reported an improved complete resection rate with neoadjuvant chemotherapy, and R0 resection rate was associated with long‐term survival after neoadjuvant therapy in gastric cancer \[[11](#onco13019-bib-0011){ref-type="ref"}\]. The present study showed a satisfactory R0 resection rate, but pCR (ypT0N0M0) was reported in 3 of 48 per‐protocol patients (6.3%) who underwent surgery. Comparison with initial clinical and pathologic stages revealed downstaging of T stage in 66.7% of patients (32/48) and downstaging of N stage in 45.8% of patients (22/48) (Table [4](#onco13019-tbl-0004){ref-type="table"}). Although there is still no universally accepted grading system for pathologic regression, numerous studies have shown that the degree of pathologic response is a vital prognostic marker of local recurrence, distant metastases, and long‐term outcomes in locally advanced gastric cancer after neoadjuvant therapy \[[12](#onco13019-bib-0012){ref-type="ref"}\]. More importantly, pathologic response can guide clinical decisions about surgical strategies, adjuvant therapy, and long‐term surveillance \[[13](#onco13019-bib-0013){ref-type="ref"}\], \[[14](#onco13019-bib-0014){ref-type="ref"}\].

The survival analysis revealed a 3‐year progression‐free survival (PFS) rate of 43.8%, and a 3‐year overall survival (OS) rate of 47.2%. The median PFS was 20.1 months, with an event rate of 55.6%. However, median OS was 30.77 months. In the CLASSIC trial, 3‐year disease‐free survival was 74% in the chemotherapy group, and 59% in the surgery‐only group; corresponding values for 3‐year OS were 83% and 78% \[[15](#onco13019-bib-0015){ref-type="ref"}\]. In FLOT4 trial, the median OS was 35 months with ECX/ECF and 50 months with FLOT. The PFS was 18 months with ECX/ECF and 30 months with FLOT. 3‐year OS rate was 48% with ECF/ECX and 57% with FLOT. The survival disparity between the CLASSIC, the FLOT4 trial, and our study may have resulted from population differences. The CLASSIC trial enrolled patients with stage II (T2N1, T1N2, T3N0), IIIA (T3N1, T2N2, T4N0), or IIIB (T3N2) disease according to American Joint Committee on Cancer criteria (6th edition). However, patients in our study had much later disease (T2--4/N+M0) and were typically in stage III \[[16](#onco13019-bib-0016){ref-type="ref"}\]: 20.4% of patients were stage IIIA, 33.3% were stage IIIB, and 31.5% were stage IIIC. In the FLOT4 trial, the rate of node‐positive patients was 79.4%. However, the rate in our study was 100%, even though the 3‐year OS rate in our study was comparable to the rate of ECF/ECX group in the FLOT4 study.

Two‐drug and three‐drug regimens are both recommended for patients with ≥ stage IB resectable gastric cancer, and there is no current evidence showing a significant difference in efficacy between these regimens. According to National Comprehensive Cancer Network guidelines \[[17](#onco13019-bib-0017){ref-type="ref"}\], treatment regimens should be chosen after considering performance status, medical comorbidities, and toxicity profiles. Therefore, a balance between efficacy and tolerability is important when selecting treatment. The recommended treatment duration is usually 2--4 cycles, but this could be modified depending on the circumstances \[[16](#onco13019-bib-0016){ref-type="ref"}\], \[[17](#onco13019-bib-0017){ref-type="ref"}\]. Our study indicated that eight cycles of XELOX (i.e., four cycles preoperatively, and four postoperatively) was effective as a perioperative chemotherapy schedule.

Usually, two‐drug chemotherapy regimens are preferred for patients with unresectable, locally advanced, recurrent or metastatic disease because of lower toxicity, whereas three‐drug regimens are reserved for medically fit patients with good performance status and access to frequent toxicity evaluations \[[17](#onco13019-bib-0017){ref-type="ref"}\]. The current study confirmed the good tolerability of XELOX as a perioperative chemotherapy regimen. The frequency, severity, and type of adverse events (AEs) documented with XELOX were consistent with the safety profile reported in the CLASSIC study \[[15](#onco13019-bib-0015){ref-type="ref"}\]. The proportion of grade 3--4 AEs was 8.5% during perioperative chemotherapy. The most frequent grade 3--4 AEs were neutropenia and leukopenia, and no treatment‐related deaths occurred. All these rates were significantly lower than the FLOT4 trial \[[5](#onco13019-bib-0005){ref-type="ref"}\]. Our study also found that XELOX can be delivered with higher dose intensity and better feasibility in the preoperative than the postoperative setting: 49 of 54 patients (90.7%) completed the four planned preoperative cycles, but only 27 of 42 patients (62.3%) completed the four planned postoperative cycles. The mean dose intensity of oxaliplatin was 840 mg preoperatively and 577 mg postoperatively. Moreover, only 2 of 49 patients (4.2%) experienced mild operative complications. No deaths occurred during hospitalization or 30 days after surgery. The median hospitalization time was 9.6 days. Thus, because of its good tolerability profile, XELOX might also be a promising regimen for adjuvant chemotherapy.

Figures and Tables {#onco13018-sec-3014}
==================

![Study flowchart.\
Abbreviation: XELOX, oxaliplatin and capecitabine.](onco13019-fig-0001){#onco13019-fig-0001}

![Kaplan‐Meier plots of progression‐free survival and overall survival.\
Abbreviations: OS, overall survival; PFS, progression‐free survival.](onco13019-fig-0002){#onco13019-fig-0002}

###### Baseline patient characteristics (*n* = 54)
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According to American Joint Committee on Cancer, Cancer Staging Manual, 7th edition \[16\].

###### Chemotherapy administration
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Abbreviation: SD, standard deviation.

###### Pathologic response in patients who underwent planned surgery (*n* = 48)
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Abbreviation: JCGC, Japanese Classification of Gastric Cancer.

###### Grade 3--4 toxicities of chemotherapy[a](#onco13019-note-0006){ref-type="table-fn"}
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According to National Cancer Institute Common Toxicity Criteria (version 4.0).

###### Complications and safety of surgery (*n* = 49[a](#onco13019-note-0007){ref-type="table-fn"})
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Including one emergency subtotal gastrectomy.
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